What is Nkarta?
Nkarta is dedicated to creating advanced cell therapies for oncology patients. The company leverages a proprietary cell expansion and cryopreservation platform, combined with sophisticated cell engineering technologies. This integrated approach aims to produce off-the-shelf NK cell therapies that are designed for enhanced tumor targeting and improved persistence, thereby offering sustained therapeutic activity. Nkarta's strategy focuses on efficient manufacturing processes to deliver these cutting-edge treatments to a broader patient population.
How much funding has Nkarta raised?
Nkarta has raised a total of $125M across 2 funding rounds:
Series A
$11M
Series B
$114M
Series A (2015): $11M, investors not publicly disclosed
Series B (2019): $114M led by NEA Ventures, SR One, Samsara BioCapital, Life Science Partners, Novo Holdings, RA Capital Management, Amgen Business Development, Deerfield, and Logos Capital
Key Investors in Nkarta
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics. The firm partners with founders and scientific teams to translate innovative technologies and discoveries into new medicines, typically leading or coleading financings and providing handson strategic and operational support.
Life Science Partners
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. The company also has a growing interest in climate and sustainability technologies.
What's next for Nkarta?
With the recent major strategic investment and substantial overall capital, Nkarta is well-positioned to accelerate its clinical development programs and further refine its manufacturing platform. The company's focus on allogeneic NK cell therapies suggests a strategic move towards scalable and accessible cancer treatments. Future endeavors will likely involve advancing its lead candidates through clinical trials, potentially expanding its therapeutic pipeline, and solidifying its position as a key player in the competitive cell therapy landscape. The substantial backing indicates a strong belief in Nkarta's technology and its potential to address significant unmet needs in cancer care.
See full Nkarta company page
